SWOG S1011 trial questions the benefits of extended lymphadenectomy in bladder cancer

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days after surgery.